Published in Medical Patent Week, April 29th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Immtech.
Report 1: Immtech Pharmaceuticals, Inc., (IMM) announced that it has completed enrollment in a phase III pivotal trial of its oral drug candidate, pafuramidine maleate (pafuramidine), to treat first-stage patients (those with no evidence of central nervous system involvement) for African trypanosomiasis, also known as African sleeping sickness.
The trial protocol was reviewed and approved by the United States Food & Drug Administration (FDA) under a special...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.